In focus · trending topic

urea cycle disorder

4 stories · following the connections

Horizon Pharma plc Submits Supplemental New Drug Application for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to Expand Age Range to Include Newborns

By Nasdaq OMXFeb 27, 2018, 11:00 PM UTC

Horizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to People with Urea Cycle Disorders Two Months of Age and Older

By Nasdaq OMXMay 1, 2017, 11:01 AM UTC

Horizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to People with Urea Cycle Disorders Two Months of Age and Older

By Nasdaq OMXMay 1, 2017, 11:01 AM UTC

Horizon Pharma plc to Present Data on RAVICTI® (glycerol phenylbutyrate) Oral Liquid for Urea Cycle Disorder Patients Aged Two Months to Two Years

By Nasdaq OMXMar 22, 2017, 1:00 PM UTC